FDA Gives a Green Signal to a New Drug for Uncomplicated UTI

fda approved new drug for UTI

On 24th April 2024, the FDA approves pivmecillinam under the brand name Pivya for treating uncomplicated UTIs in adult women. Uncomplicated urinary tract infections are caused by microorganisms like Staphylococcus saprophyticus, Proteus mirabilis, and Escherichia coli. The UTI infections caused by the above-mentioned bacteria are more common than others and affect almost 50% of women … Read more

What is WINREVAIR (Sotatercept-csrk)?

what is WINREVAIR (Sotatercept-csrk) fda approved for PAH

WINREVAIR (Sotatercept-csrk) is a recombinant activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It blocks certain signals in the body. Specifically, it binds to and inhibits activin A and other TGF- β superfamily ligands. It corrects the imbalance between pro-proliferative (ActRIIA/Smad2/3-mediated) and anti-proliferative (BMPRII/Smad1/5/8 mediated) signaling mechanisms. By improving the bad inflammatory signals, it inhibits vascular … Read more

Daratumumab Mechanism of Action: Darzalex MOA

Daratumumab Mechanism of Action darzalex moa

Daratumumab Mechanism of Action: Daratumumab is a human monoclonal antibody. It is indicated for the treatment of Multiple Myeloma in the following situations: In Combination With … Daratumumab Indications Lenalidomide + dexamethasone Newly diagnosed Multiple Myeloma patients ineligible for autologous stem cell transplant OR Patients with relapsed or refractory multiple myeloma who have received at … Read more

Berdazimer Gel 10.3% (Zelsuvmi) for Molluscum Contagiosum

Berdazimer Gel 10.3% (Zelsuvmi) for Molluscum Contagiosum

The FDA approved Berdazimer Gel 10.3% (Zelsuvmi) for Molluscum Contagiosum on 5th January 2024. Berdazimer Gel 10.3% (Zelsuvmi) is the second topical medicine approved so far for the treatment of Molluscum Contagiosum (MC). The first one, cantharidin, was approved in 2023. Curettage is more effective than Cantharidin. However, it has not been compared with Berdazimer … Read more

Why is Linzess Dangerous?

linzess moa abdominal pain why is linzess dangerous

Why is Linzess dangerous? All medicines can be dangerous. Linzess is a prescription medicine and it has its Pros and Cons. It is indicated for the treatment of chronic constipation and individuals with constipation-dominant IBS. Because it relieves constipation, one of the side effects can be diarrhea. Diarrhea can occur with any of the medications … Read more

Does Truqap (Capivasertib) Cause Hyperglycemia?

mTOR inhibitor Everolimus Afinitor trucap hyperglycemia

Yes! In clinical trials, hyperglycemia was reported in about 58% of the patients. TRUQAP (Capivasertib) is the most recently approved medicine for the treatment of breast cancer. It is recommended for women with the following [Ref]: Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative, Locally advanced or metastatic breast cancer with One or … Read more

Linzess MOA: Mechanism of Action of Linaclotide

linzess moa abdominal pain why is linzess dangerous

Linzess MOA (Mechanism of action) is different from most other medications used to treat constipation and IBS (Irritable Bowel Syndrome) such as Miralax. Linzess (Linaclotide) is the first-in-class medicine that acts on the intestinal epithelial cells and stimulates the transmembrane Guanylate Cyclase 2C receptors (GC-2C). Activation of guanylate cyclase 2 C receptors results in the … Read more

Zavegepant Nasal Spray (Zavzpret) for Migraine

Zavzpret zavegepant nasal spray moa vrayler cariprazine uses dose moa brands side effects

Zavegepant Nasal Spray (Zavzpret) is a small-molecule, competitive antagonist of the calcitonin gene-related peptide (CGRP) receptor, which is a target for the treatment of migraine. CGRP is a neuropeptide that is found in high levels in the trigeminal nerve, which is believed to play a role in migraine pathogenesis. CGRP exerts its effects on the vasculature, … Read more

BEOVU Indications: Brolucizumab Prevents Vision

BEOVU (Brolucizumab) indications

BEOVU Indications: Wet age-related macular degeneration Brand Name: Beovu Drug Name: Brolucizumab Date of FDA Approval: 8th Oct 2019 Manufacturer: Novartis Pharmaceuticals [Ref] BEOVU® (Brolucizumab-dbll) injection is a medication that has been recently approved by the FDA for the treatment of wet age-related macular degeneration (AMD). It is one of the new molecules that block … Read more